Cancer

Cover image for Vol. 120 Issue 21

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.901

ISI Journal Citation Reports © Ranking: 2013: 38/202 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 146
  1. Editorial

    1. Revisiting structure, process, and outcome

      Scott M. Gilbert

      Article first published online: 22 OCT 2014 | DOI: 10.1002/cncr.29070

      The quality of bladder cancer varies markedly, and bladder cancer has not garnered national attention despite the incidence and cost burden associated with bladder cancer. This editorial argues for revisiting Donabedian's structure, process, and outcome framework for quality assessment among patients with bladder cancer.

  2. Original Articles

    1. Disease Site

      Genitourinary Disease
      Quality of diagnostic staging in patients with bladder cancer: A process-outcomes link

      Karim Chamie, Eric Ballon-Landa, Jeffrey C. Bassett, Timothy J. Daskivich, Meryl Leventhal, Dennis Deapen and Mark S. Litwin

      Article first published online: 22 OCT 2014 | DOI: 10.1002/cncr.29071

      The medical records of 1865 patients with bladder cancer in Los Angeles County are reviewed, and suboptimal staging in nearly half of all diagnostic resections is found to be associated with increased mortality, particularly in patients with high-grade disease.

    2. Head and Neck Disease
      Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status

      Shao Hui Huang, John N. Waldron, Michael Milosevic, Xiaowei Shen, Jolie Ringash, Jie Su, Li Tong, Bayardo Perez-Ordonez, Ilan Weinreb, Andrew J. Bayley, John Kim, Andrew Hope, B.C. John Cho, Meredith Giuliani, Albiruni Razak, David Goldstein, Willa Shi, Fei-Fei Liu, Wei Xu and Brian O'Sullivan

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29100

      This relatively large cohort study reports an intriguing hypothesis-generating observation: high pretreatment neutrophil counts, high pretreatment monocyte counts, and low pretreatment lymphocyte counts independently predict inferior survival and disease control for human papillomavirus–positive oropharyngeal cancer patients, whereas a predictive value for human papillomavirus–negative patients is not apparent.

  3. Review Articles

    1. Small cell lung cancer: Where do we go from here?

      Lauren Averett Byers and Charles M. Rudin

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29098

      The treatment of small cell lung cancer has not changed significantly in 3 decades. In this review, the authors discuss the current challenges and opportunities to accelerate progress in this highly lethal disease.

    2. Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials

      Ursula A. Matulonis, Amit M. Oza, Tony W. Ho and Jonathan A. Ledermann

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29082

      Overall survival is regarded as the most clinically relevant endpoint in trials of ovarian cancer, but it may be confounded by multiple lines of subsequent therapy. A primary endpoint of progression-free survival supported by intermediate clinical endpoints and overall survival provides a more comprehensive approach for evaluating efficacy.

  4. Editorials

    1. Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?

      Janet E. Dancey

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29084

      Intermediate endpoints that better capture the benefits of treatment and patient outcomes will facilitate trial conduct and ultimately treatment decisions for individual patients. Whether the current crop of newer endpoints will improve trial conduct and the interpretation of outcomes will require further evaluation.

  5. Original ArticleS

    1. Disease Site

      Hematologic Malignancies
      Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

      Jean-Pierre Issa, Guillermo Garcia-Manero, Xuelin Huang, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Mark Brandt, Sherry Pierce and Hagop M. Kantarjian

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29085

      For this randomized study, a Bayesian design is used to compare decitabine with decitabine plus valproic acid in patients with myelodysplastic syndrome and in elderly patients with acute myelogenous leukemia. No benefit is demonstrated from the addition of valproic acid; and the toxicity of the combination—particularly neurotoxicity—is more significant.

  6. Editorials

    1. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges

      Michael Lübbert and Andrea Kuendgen

      Article first published online: 21 OCT 2014 | DOI: 10.1002/cncr.29083

      In the first randomized trial of older patients with myelodysplastic syndrome/acute myeloid leukemia (adaptive randomization) to receive treatment with intravenous decitabine (5-day schedule) either alone or in combination with the oral histone deacetylase (HDAC) inhibitor valproic acid (7-day schedule), Issa and colleagues do not detect an improved response rate or overall survival with the combined treatment. The various factors potentially affecting clinical outcome in studies combining decitabine or 5-azacytidine with valproic acid or other HDAC inhibitors are discussed.

  7. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer

      Aalok Kumar, Hagen F. Kennecke, Daniel J. Renouf, Howard J. Lim, Sharlene Gill, Ryan Woods, Caroline Speers and Winson Y. Cheung

      Article first published online: 20 OCT 2014 | DOI: 10.1002/cncr.29072

      Stage II colon cancer has a relatively good prognosis. Patients who have high-risk disease based on clinical and pathological factors may derive benefit from adjuvant chemotherapy in the setting of specific high-risk features such as T4 disease.

    2. Hepatobiliary Disease
      Clinical and pathologic features of familial pancreatic cancer

      Jeremy L. Humphris, Amber L. Johns, Skye H. Simpson, Mark J. Cowley, Marina Pajic, David K. Chang, Adnan M. Nagrial, Venessa T. Chin, Lorraine A. Chantrill, Mark Pinese, R. Scott Mead, Anthony J. Gill, Jaswinder S. Samra, James G. Kench, Elizabeth A. Musgrove, Katherine M. Tucker, Allan D. Spigelman, Nic Waddell, Sean M. Grimmond, Andrew V. Biankin and the Australian Pancreatic Cancer Genome Initiative

      Article first published online: 14 OCT 2014 | DOI: 10.1002/cncr.28863

      The risk of malignancy in familial pancreatic cancer (PC) kindreds does not appear to be confined to the pancreas. Patients with familial PC have more precursor lesions, smoker less, and have lower tobacco exposure but are similar in age at diagnosis and outcome compared with patients who have sporadic PC.

    3. Soft Tissue and Bone Sarcoma
      You have full text access to this OnlineOpen article
      A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma

      Sant P. Chawla, Victoria S. Chua, Andrew F. Hendifar, Doris V. Quon, Neelesh Soman, Kamalesh K. Sankhala, D. Scott Wieland and Daniel J. Levitt

      Article first published online: 13 OCT 2014 | DOI: 10.1002/cncr.29081

      At the maximum tolerated dose of 350 mg/m2, aldoxorubicin demonstrates clinical activity in patients with recurrent or refractory advanced solid tumors, including soft tissue sarcomas, without evidence of acute cardiotoxicity, which is a major limitation to the use of native doxorubicin. Aldoxorubicin may allow for higher dose equivalents of doxorubicin to be administered.

    4. Discipline

      Epidemiology
      Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes

      Julie Hallet, Calvin How Lim Law, Moises Cukier, Refik Saskin, Ning Liu and Simron Singh

      Article first published online: 13 OCT 2014 | DOI: 10.1002/cncr.29099

      Although the incidence of all neuroendocrine tumors has markedly increased over the course of 15 years, the proportion of metastatic disease at presentation has decreased, and this points toward increased detection outlining a rise in incidence. Socioeconomic status and rural residency portend worse survival for patients with neuroendocrine tumors, and they should be paid particular attention when initiatives are being designed to improve care for patients with neuroendocrine tumors.

    5. Antioxidant micronutrients and the risk of renal cell carcinoma in the Women's Health Initiative cohort

      Won Jin Ho, Michael S. Simon, Vedat O. Yildiz, James M. Shikany, Ikuko Kato, Jennifer L. Beebe-Dimmer, Jeremy P. Cetnar and Cathryn H. Bock

      Article first published online: 9 OCT 2014 | DOI: 10.1002/cncr.29091

      Increased lycopene intake among postmenopausal women is associated with a lower risk of renal cell carcinoma in the Women's Health Initiative cohort. Further investigation into the correlation between lycopene intake and the risk of renal cell carcinoma is warranted.

  8. Commentary

    1. Eliminating cost-sharing requirements for colon cancer screening in Medicare

      David H. Howard, Gery P. Guy Jr and Donatus U. Ekwueme

      Article first published online: 9 OCT 2014 | DOI: 10.1002/cncr.29093

      Medicare beneficiaries incur out-of-pocket costs for polypectomies and colonoscopies after a positive fecal occult blood test. We estimate Medicare spending will increase by $48 million annually if Medicare waives cost-sharing requirements for these services.

  9. Original Articles

    1. Discipline

      Radiation Oncology
      A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy

      Jeremy Setton, Nancy Y. Lee, Nadeem Riaz, Shao-Hui Huang, John Waldron, Brian O'Sullivan, Zhigang Zhang, Weij Shi, David I. Rosenthal, Katherine A. Hutcheson and Adam S. Garden

      Article first published online: 6 OCT 2014 | DOI: 10.1002/cncr.29022

      In a multi-institution study of severe swallowing dysfunction requiring enteral support, patients are identified who previously received intensity-modulated radiotherapy with or without systemic therapy for oropharyngeal cancer. The results indicate that modern nonsurgical therapy for oropharyngeal cancer is associated with a low rate of long-term gastrostomy tube dependence.

  10. Review Articles

    1. Imaging of the axilla before preoperative chemotherapy: Implications for postmastectomy radiation

      Jose G. Bazan and Julia White

      Article first published online: 6 OCT 2014 | DOI: 10.1002/cncr.28859

      The decision to use postmastectomy radiotherapy for patients with breast cancer who receive neoadjuvant chemotherapy (NAC) is determined by the clinical extent of disease at presentation before NAC, the presence of pathologic residual disease (especially pathologically involved lymph nodes) after NAC, and the disease response to NAC. Therefore, accurate knowledge of the extent of axillary disease before NAC and assessment of response to therapy are critically important.

  11. Original Articles

    1. Disease Site

      Head and Neck Disease
      Prevalence and prognostic value of human papillomavirus genotypes in tonsillar squamous cell carcinoma: A Korean multicenter study

      Jae Hong No, Myung-Whun Sung, J. Hun Hah, Seung Ho Choi, Myung-Chul Lee, Hee Seung Kim and Yong-Sang Song

      Article first published online: 3 OCT 2014 | DOI: 10.1002/cncr.29086

      The proportion of human papillomavirus–positive tonsillar cancer has increased during the last 20 years in Korea. The presence of human papillomavirus 18 may serve as a biomarker for a poor prognosis.

    2. Hematologic Malignancies
      Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial

      Mohamad Mohty, Florent Malard, Didier Blaise, Noel Milpied, Sabine Furst, Resa Tabrizi, Thierry Guillaume, Stéphane Vigouroux, Jean El-Cheikh, Jacques Delaunay, Steven Le Gouill, Philippe Moreau, Myriam Labopin and Patrice Chevallier

      Article first published online: 3 OCT 2014 | DOI: 10.1002/cncr.29087

      The reduced toxicity regimen based on a busulfan dose of 130 mg/m2/day intravenously for 3 days, fludarabine at a dose of 30 mg/m2/day for 5 days, and antithymocyte globulins at a dose of 2.5 mg/kg/day for 2 days was evaluated in a prospective phase 2 trial. This regimen appeared to be safe, with a low nonrecurrence mortality rate at 2 years in high-risk patients, and efficient disease control, thereby warranting prospective phase 3 trials.

    3. Discipline

      Outcomes Research
      Smoking history predicts for increased risk of second primary lung cancer: A comprehensive analysis

      John M. Boyle, Daniel J. Tandberg, Junzo P. Chino, Thomas A. D'Amico, Neal E. Ready and Chris R. Kelsey

      Article first published online: 3 OCT 2014 | DOI: 10.1002/cncr.29095

      The current study identifies and quantifies risk factors for second primary lung cancer in a population of patients treated for an index non-small cell lung cancer. Among 1484 subjects, it was found that smoking was the only risk factor assessed that predicted for the development of a second primary lung cancer, with never-smokers having an exceedingly low risk.

  12. Editorials

    1. Targeted survival improvements in clinical trials: Are you an absolutist or relativist?

      James Paul

      Article first published online: 2 OCT 2014 | DOI: 10.1002/cncr.29031

      In this issue of Cancer, Castonguay et al highlights problems with reliably estimating the median OS in the control arm of clinical trials in ovarian cancer. This suggests that more careful reflection is genrally required concerning how clinically relevant differences are determined and highlights further issues with the selection of overall survival as a primary endpoint. The article also raises questions regarding the prevalent standard statistical approach used to design and analyze studies with time to event outcomes.

  13. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer

      Vincent Castonguay, Michelle K. Wilson, Ivan Diaz-Padilla, Lisa Wang and Amit M. Oza

      Article first published online: 2 OCT 2014 | DOI: 10.1002/cncr.29030

      The anticipated clinical outcome of the standard/control arm is an important parameter in the design of randomized phase 3 trials for the accurate calculation of sample size, power, and study duration but is often underestimated in ovarian cancer trials. Changing patterns of care and variations in enrolled study populations may result in a deviation from the anticipated outcome and subsequent inaccurate statistical assumptions.

    2. Discipline

      Medical Oncology
      Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

      Liza C. Villaruz, Mark A. Socinski, Shira Abberbock, Lynne D. Berry, Bruce E. Johnson, David J. Kwiatkowski, A. John Iafrate, Marileila Varella-Garcia, Wilbur A. Franklin, D. Ross Camidge, Lecia V. Sequist, Eric B. Haura, Mark Ladanyi, Brenda F. Kurland, Kelly Kugler, John D. Minna, Paul A. Bunn and Mark G. Kris

      Article first published online: 1 OCT 2014 | DOI: 10.1002/cncr.29042

      The advent of effective targeted therapy for BRAFV600E-mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. BRAF mutations occur in 2.2% of advanced-stage lung adenocarcinomas undergoing testing through the Lung Cancer Mutation Consortium, are most commonly V600E, and are associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas.

  14. Review Articles

    1. Therapeutic strategies for neuroendocrine liver metastases

      Andrea Frilling and Ashley K. Clift

      Article first published online: 1 OCT 2014 | DOI: 10.1002/cncr.28760

      Although multiple modalities are available for the treatment of neuroendocrine liver metastases, optimal management is unclear. The current knowledge pertaining to these treatment options is analyzed

  15. Correspondence

    1. Flawed assumptions used to defend screening mammography

      Archie Bleyer, Charles R. Thomas Jr, Cornelia Baines and Anthony B. Miller

      Article first published online: 1 OCT 2014 | DOI: 10.1002/cncr.29021

      Exaggerating the current benefit of screening mammography and minimizing its harms are readily accomplished by the application of assumptions based on data one-quarter to half of a century old, and they are neither reliable for predicting what is happening today nor appropriate for the treatment advances that have happened since. Helvie and colleagues are culpable of this conduct.

    2. Reply to flawed assumptions used to defend screening mammography

      Mark A. Helvie, Joanne T. Chang, R. Edward Hendrick and Mousumi Banerjee

      Article first published online: 1 OCT 2014 | DOI: 10.1002/cncr.29020

  16. Erratum

    1. You have free access to this content
  17. Review Articles

    1. Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

      Kathryn M. Field, Justin T. Jordan, Patrick Y. Wen, Mark A. Rosenthal and David A. Reardon

      Article first published online: 26 SEP 2014 | DOI: 10.1002/cncr.28935

      Bevacizumab provides benefit for patients with recurrent glioblastoma. The results of recent trials have indicated that its role among newly diagnosed patients remains unclear.

    2. Summing it up: An integrative review of studies of cancer survivorship care plans (2006-2013)

      Deborah K. Mayer, Sarah A. Birken, Devon K. Check and Ronald C. Chen

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.28884

      In this integrative review of the existing literature, the authors assess the state of scientific knowledge regarding survivorship care plans (SCPs). Studies regarding SCPs fall into 3 categories: 1) content, 2) dissemination and implementation, and 3) survivor and provider outcomes. The quantity and quality of research related to SCPs are limited.

  18. Original Articles

    1. Disease Site

      Melanoma
      Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933

      Sylvia M. Lee, James Moon, Bruce G. Redman, Tarek Chidiac, Lawrence E. Flaherty, Yuanyuan Zha, Megan Othus, Antoni Ribas, Vernon K. Sondak, Thomas F. Gajewski and Kim A. Margolin

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29055

      This phase 2 trial investigates the safety and efficacy of RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with advanced melanoma and no prior systemic chemotherapy. RO4929097 is well tolerated but shows minimal clinical activity against metastatic melanoma, possibly in part because of a lack of adequate exposure of the tumor to therapeutic drug levels.

  19. Review Articles

    1. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

      Jayson I. L. Bastien, Katharine A. McNeill and Howard A. Fine

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.28968

      The last decade has seen an explosion of data elucidating the molecular and genetic drivers of glioblastoma, but clinical trials of molecularly targeted agents have been largely disappointing to date. This article reviews the most important genetic and epigenetic changes found in glioblastoma and the trials that have attempted to target those lesions, and it offers some potential reasons for their current lack of clinical efficacy.

  20. Original Articles

    1. Discipline

      Pediatric Oncology
      Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group

      Steven G. DuBois, Mark D. Krailo, Mark C. Gebhardt, Sarah S. Donaldson, Karen J. Marcus, John Dormans, Robert C. Shamberger, Scott Sailer, Richard W. Nicholas, John H. Healey, Nancy J. Tarbell, R. Lor Randall, Meenakshi Devidas, James S. Meyer, Linda Granowetter, Richard B. Womer, Mark Bernstein, Neyssa Marina and Holcombe E. Grier

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29065

      Patient characteristics differ according to the chosen mode of local control in Ewing sarcoma. Accounting for these differences, patients who are selected for definitive radiotherapy have higher rates of local failure but no differences in event-free or overall survival compared with patients who are selected for definitive surgery.

    2. Disease Site

      Gastrointestinal Disease
      Identification of novel mutations by exome sequencing in African American colorectal cancer patients

      Hassan Ashktorab, Mohammad Daremipouran, Joe Devaney, Sudhir Varma, Hamed Rahi, Edward Lee, Babak Shokrani, Russell Schwartz, Michael L. Nickerson and Hassan Brim

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.28922

      We have little knowledge of the phenotypic genetic changes of colorectal cancer in African Americans and their correlation with the DNA changes found in the majority of cancers in this population. Identifying biomarkers in colorectal cancer in African Americans is likely to help determine the key genes involved in the progression of this disease and identify biomarkers for targeted therapy and management in African Americans with colorectal cancer.

    3. Gynecologic Oncology
      Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

      Diana P. English, Stefania Bellone, Carlton L. Schwab, Dana M. Roque, Salvatore Lopez, Ileana Bortolomai, Emiliano Cocco, Elena Bonazzoli, Sudeshna Chatterjee, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford and Alessandro D. Santin

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29062

      Solitomab, a novel, bispecific, single-chain antibody, is highly active against chemotherapy-resistant epithelial ovarian carcinoma cell lines as well as unmanipulated malignant tumor cells in ascitic fluid. Solitomab may represent a novel, potentially highly effective, targeted agent for the treatment of chemotherapy-resistant ovarian disease that overexpresses epithelial cell adhesion molecule.

    4. Obesity is associated with worse quality of life in women with gynecologic malignancies: An opportunity to improve patient-centered outcomes

      Kemi M. Doll, Alison K. Kalinowski, Anna C. Snavely, Debra E. Irwin, Jeannette T Bensen, Victoria L. Bae-Jump, Kenneth H. Kim, Linda Van Le, Daniel L. Clarke-Pearson and Paola A. Gehrig

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29061

      Before cancer treatment, obese patients with gynecologic malignancies have worse baseline quality of life compared with their normal-weight counterparts. Emerging models of quality of life-based cancer outcome measures will significantly affect populations with a high obesity burden.

    5. Hematologic Malignancies
      Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study

      Jorge J. Castillo, Mark Bower, Jérémy Brühlmann, Urban Novak, Hansjakob Furrer, Paula Y. Tanaka, Caroline Besson, Silvia Montoto, Kate Cwynarski, Jeremy S. Abramson, Samir Dalia, Michele Bibas, Joseph M. Connors, Michael Furman, Minh-Ly Nguyen, Timothy P. Cooley, Brady E. Beltran, Jaime A. Collins, Julie M. Vose, Blanca Xicoy, Josep-Maria Ribera and for the HIV-Associated Hodgkin Lymphoma in the cART Era Study Group

      Article first published online: 23 SEP 2014 | DOI: 10.1002/cncr.29066

      Based on results from this multicenter, retrospective study, the CD4-positive cell count at lymphoma diagnosis appears to be prognostic for progression-free and overall survival in patients with human immunodeficiency virus-associated, advanced-stage classical Hodgkin lymphoma who receive doxorubicin, bleomycin, vinblastine, and dacarbazine plus combination antiretroviral therapy. The patients who receive this treatment have excellent response and survival rates and should be treated akin to immunocompetent patients.

  21. Editorials

    1. Tobacco control: Up in E-smoke?

      Srihari Veeraraghavan

      Article first published online: 22 SEP 2014 | DOI: 10.1002/cncr.28810

      Electronic cigarettes are rapidly gaining popularity. However, the lack of regulation has the potential to undermine decades of tobacco cessation efforts.

  22. Original Articles

    1. Discipline

      Outcomes Research
      Electronic cigarette use among patients with cancer: Characteristics of electronic cigarette users and their smoking cessation outcomes

      Sarah P. Borderud, Yuelin Li, Jack E. Burkhalter, Christine E. Sheffer and Jamie S. Ostroff

      Article first published online: 22 SEP 2014 | DOI: 10.1002/cncr.28811

      Electronic cigarette use is highly prevalent among patients with cancer. Although further research is needed, the clinical findings of the current study do not provide evidence in support of the benefit of electronic cigarettes in promoting cessation from combustible cigarettes. In the absence of encouraging findings, evidence-based tobacco cessation interventions should be recommended for all patients with cancer.

    2. Epidemiology
      Effectiveness of population-based service screening with mammography for women ages 40 to 49 years with a high or low risk of breast cancer: Socioeconomic status, parity, and age at birth of first child

      Barbro Numan Hellquist, Kamila Czene, Anna Hjälm, Lennarth Nyström and Håkan Jonsson

      Article first published online: 19 SEP 2014 | DOI: 10.1002/cncr.29011

      The invitation to mammography screening of women aged 40 to 49 years is an issue of debate in many countries and a cost-effective alternative in those countries without screening among these women could be inviting only those women at higher risk. For the 3 risk factors in the current study, the relative effectiveness for the high-risk groups was found to be the same as or higher than that of the low-risk groups, indicating that screening of high-risk groups (eg, nulliparous women) may be an alternative.

    3. Radiation Oncology
      Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non–small cell lung cancer patients undergoing definitive radiation therapy: Pilot study results

      Jay F. Dorsey, Gary D. Kao, Kelly M. MacArthur, Melody Ju, David Steinmetz, E. Paul Wileyto, Charles B. Simone II and Stephen M. Hahn

      Article first published online: 19 SEP 2014 | DOI: 10.1002/cncr.28975

  23. Review Articles

    1. Psychiatric implications of cancer genetic testing

      April Malia Hirschberg, Gayun Chan-Smutko and William F. Pirl

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.28879

      Cancer genetic testing itself does not appear to cause significant psychological or psychiatric issues, although individuals who present for testing may have baseline psychosocial issues or risk factors that must be addressed during the testing process. Psychiatric predictors of cancer genetic testing, the psychosocial impact of testing, risk perception and adherence to recommendations for risk reduction of identified hereditary cancer syndromes, and recommendations for mental health interventions are reviewed.

  24. Original Articles

    1. Disease Site

      Breast Disease
      Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico

      Cynthia Villarreal-Garza, Rosa María Alvarez-Gómez, Carlos Pérez-Plasencia, Luis A. Herrera, Josef Herzog, Danielle Castillo, Alejandro Mohar, Clementina Castro, Lenny N. Gallardo, Dolores Gallardo, Miguel Santibáñez, Kathleen R. Blazer and Jeffrey N. Weitzel

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.29058

      This is the first study of BRCA mutation prevalence among unselected breast cancer and ovarian cancer cases in Mexico, demonstrating a remarkably high frequency of BRCA mutations, including a high percentage with the Mexican founder mutation, BRCA1 ex9-12del. The HISPANEL, an economic and sensitive tool that detects recurrent BRCA mutations, has the potential to provide cost-effective cancer prevention and management by improving access to genetic cancer risk assessment among underserved populations like Mexico.

    2. Discipline

      Supportive Care
      Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway

      Ole-Petter R. Hamnvik, Toni K. Choueiri, Alexander Turchin, Rana R. McKay, Lipika Goyal, Michael Davis, Marina D. Kaymakcalan and Jonathan S. Williams

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.28972

      Older age, higher body mass index, and preexisting hypertension are risk factors for the development of a treatment-induced hypertensive response to VEGF signaling pathway inhibitors. The development of hypertension was associated with improved survival.

  25. Review Articles

    1. Quo vadis: Advanced prostate cancer—clinical care and clinical research in the era of multiple androgen receptor-directed therapies

      Won Kim and Charles J. Ryan

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.28929

      Despite advances in novel androgen receptor-directed therapies that have changed the landscape of advanced prostate cancer treatment, many critical questions remain unanswered, and obstacles remain in optimizing the care for patients burdened with the disease.

  26. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Endoscopic ultrasonography in esophageal cancer leads to improved survival rates: Results from a population-based study

      Sachin Wani, Ananya Das, Amit Rastogi, Jennifer Drahos, Winifred Ricker, Ruth Parsons, Ajay Bansal, Roy Yen, Lindsay Hosford, Meghan Jankowski, Prateek Sharma and Michael B. Cook

      Article first published online: 18 SEP 2014 | DOI: 10.1002/cncr.29043

      Patients undergoing endoscopic ultrasound (EUS), computed tomography (CT)–positron emission tomography (PET), or EUS and CT-PET have improved survival at all stages (with the exception of stage 0 disease) in comparison with patients undergoing no EUS or CT-PET. Receipt of EUS is a significant predictor for improved 1-, 3-, and 5-year survival. Similar results are noted when the results are stratified on the basis of histology and for groups undergoing CT-PET or EUS plus CT-PET.

    2. Gynecologic Oncology
      Polymerase ɛ (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing

      Caroline C. Billingsley, David E. Cohn, David G. Mutch, Julie A. Stephens, Adrian A. Suarez and Paul J. Goodfellow

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29046

      Mutation in the polymerase ɛ gene (POLE) exonuclease domain is a defining feature of a subgroup of endometrial cancers (ECs) with very high somatic mutation burden and for which improved progression-free survival has been reported; however, in this analysis of 544 ECs, no significant survival association is identified, indicating that POLE mutation is unlikely to be a clinically applicable prognostic marker. However, some high rates of POLE defects in a subset of microsatellite unstable cancers appear to be associated with somatic mutation in DNA mismatch repair genes, a finding with important implications for Lynch syndrome testing in patients with EC.

  27. Editorials

    1. POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: Implications for Lynch syndrome testing

      Panagiotis A. Konstantinopoulos and Ursula A. Matulonis

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29057

      In endometrial cancer, the presence of polymerase ɛ (POLE) exonuclease domain mutations in immunohistochemically abnormal/microsatellite unstable/mutL homolog1-unmethylated tumors may serve as a marker of somatic origin. These mutations may be important in making determinations and recommendations for mismatch repair gene mutation testing in women with endometrial cancer.

  28. Original Articles

    1. Discipline

      Medical Oncology
      Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian

      Jacqueline Mersch, Michelle A. Jackson, Minjeong Park, Denise Nebgen, Susan K. Peterson, Claire Singletary, Banu K. Arun and Jennifer K. Litton

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29041

      In a cohort of more than 1000 known mutation carriers, BRCA2 mutations are associated with a higher rate of pancreatic cancer than previously reported. Increases have also been observed in prostate cancer and melanoma.

    2. Pediatric Oncology
      Parent decision-making around the genetic testing of children for germline TP53 mutations

      Melissa A. Alderfer, Kristin Zelley, Robert B. Lindell, Ana Novokmet, Phuong L. Mai, Judy E. Garber, Deepika Nathan, Sarah Scollon, Nicolette M. Chun, Andrea F. Patenaude, James M. Ford, Sharon E. Plon, Joshua D. Schiffman, Lisa R. Diller, Sharon A. Savage, David Malkin, Carol A. Ford and Kim E. Nichols

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29027

      Li-Fraumeni Syndrome (LFS) is a rare genetic cancer predisposition syndrome caused by germline TP53 mutations in which up to 20% of mutation carriers develop cancer during childhood. Although empirical evidence regarding benefits and risks of TP53 testing during childhood are lacking, most parents in our study decided easily in favor of testing and perceived a range of advantages that outweighed risks.

    3. Medical Oncology
      Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population-based study in Korea

      Yoon Young Cho, Jiwon Lim, Chang-Mo Oh, Junsun Ryu, Kyu-Won Jung, Jae Hoon Chung, Young-Joo Won and Sun Wook Kim

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29025

      In patients with primary thyroid cancer, the risks of several cancers are elevated significantly during follow-up. Thus, physicians are needed to pay special attention in their care of thyroid cancer patients and long-term survivors.

  29. Editorials

    1. Is there an increased risk of second primary malignancy after diagnosis of thyroid cancer?

      Aarti Mathur, Eric B. Schneider and Martha A. Zeiger

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.29026

      Recent reports on the risk of developing second primary malignancies have raised concern about whether enhanced surveillance is warranted in patients with thyroid cancer. An excellent review of the incidences and types of second primary malignancies in a Korean population treated for thyroid cancer is provided in this issue of Cancer.

  30. Original Articles

    1. Discipline

      Clinical Trials
      Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

      Jorge E. Cortes, Stuart L. Goldberg, Eric J. Feldman, David A. Rizzeri, Donna E. Hogge, Melissa Larson, Arnaud Pigneux, Christian Recher, Gary Schiller, Krzysztof Warzocha, Hagop Kantarjian, Arthur C. Louie and Jonathan E. Kolitz

      Article first published online: 15 SEP 2014 | DOI: 10.1002/cncr.28974

      CPX-351, a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin, exploits molar ratio–dependent drug-drug synergy to enhance antileukemic efficacy. A randomized phase II study comparing CPX-351 with investigators' choice of first salvage therapy in first-relapse patients demonstrated improved response, event-free survival, and overall survival (HR, 0.55; P = .02) in the poor-risk strata.

    2. Disparities Research
      Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community

      Dolly C. Penn, YunKyung Chang, Anne-Marie Meyer, Christina DeFilippo Mack, Hanna K. Sanoff, Karyn B. Stitzenberg and William R. Carpenter

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29028

      Among older patients with stage III colon cancer, there is a differential impact of race on oxaliplatin receipt depending on clinical practice affiliation. Provider-based research networks may facilitate early access to innovative treatment for African American patients with stage III colon cancer.

    3. Pediatric Oncology
      Pleuropulmonary blastoma: A report on 350 central pathology–confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry

      Yoav H. Messinger, Douglas R. Stewart, John R. Priest, Gretchen M. Williams, Anne K. Harris, Kris Ann P. Schultz, Jiandong Yang, Leslie Doros, Philip S. Rosenberg, D. Ashley Hill and Louis P. Dehner

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29032

      Three hundred fifty centrally reviewed pleuropulmonary blastoma cases confirm that the outcomes of type I are better than the outcomes of type II and that the outcomes of type II are better than the outcomes of type III. Thus, the early detection of type I pleuropulmonary blastoma before its progression to type II or III may improve outcomes.

    4. Disease Site

      Gynecologic Oncology
      Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer

      Shujuan Liu, Yong Zheng, Davide Volpi, Muna El-Kasti, Daniel Klotz, Iain Tullis, Andrea Henricks, Leticia Campo, Kevin Myers, Alex Laios, Peter Thomas, Tony Ng, Sunanda Dhar, Christian Becker, Borivoj Vojnovic and Ahmed Ashour Ahmed

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29029

      Biomarker-based selection for targeted therapy has been a key criterion for the successful application of targeted therapies. This work demonstrates the utility of an in-house developed optical imaging system for detecting the expression of the c-Met oncogene in submillimeter ovarian cancer deposits.

    5. Endocrine Disease
      Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay

      Yuri E. Nikiforov, Sally E. Carty, Simon I. Chiosea, Christopher Coyne, Umamaheswar Duvvuri, Robert L. Ferris, William E. Gooding, Steven P. Hodak, Shane O. LeBeau, N. Paul Ohori, Raja R. Seethala, Mitchell E. Tublin, Linwah Yip and Marina N. Nikiforova

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29038

      The diagnostic performance of the most complete next-generation sequencing panel of thyroid cancer genetic markers is evaluated in nodules with follicular neoplasm/suspicious for follicular neoplasm cytology. The results indicate that this panel provides highly accurate cancer detection in such nodules and should facilitate the optimal management of these patients.

    6. Discipline

      Supportive Care
      Cancer caregiving predicts physical impairments: Roles of earlier caregiving stress and being a spousal caregiver

      Youngmee Kim, Charles S. Carver, Kelly M. Shaffer, Ted Gansler and Rachel S. Cannady

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29040

      Stressed caregivers are more likely to develop heart disease and spousal caregivers are more likely than other caregivers to develop arthritis and chronic back pain years after the initial caregiving experience. The current results provide the first evidence that subjective caregiving stress and spousal role independently have aggravating effects on caregivers' physical health.

    7. Psychosocial Oncology
      Patterns of psychiatric medication use among nationally representative long-term cancer survivors and controls

      Ilana M. Braun, Sowmya R. Rao, Fremonta L. Meyer and Giuseppe Fedele

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29014

      Long-term cancer survivors and cancer-naive controls demonstrate comparable rates of psychiatric prescription medication use. These findings contribute to an emerging hypothesis that, in general, long-term cancer survivors are not a particularly psychiatrically vulnerable group.

    8. Disease Site

      Head and Neck Disease
      Human papillomavirus 16 oncoprotein regulates the translocation of β-catenin via the activation of epidermal growth factor receptor

      Zhongliang Hu, Susan Müller, Guoqing Qian, Jing Xu, Sungjin Kim, Zhengjia Chen, Ning Jiang, Dongsheng Wang, Hongzheng Zhang, Nabil F. Saba, Dong M. Shin and Zhuo Georgia Chen

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29039

      Human papillomavirus 16 E6 mediates the translocation of β-catenin to the nucleus, which may be regulated by activated epidermal growth factor receptor.

  31. Editorials

    1. Medication use as a surrogate marker of emotional health in long-term cancer survivors

      Stewart B. Fleishman

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29013

      Evaluation of the pattern of psychiatric medications used by long-term cancer survivors is an inadequate surrogate marker with which to gauge survivors' emotional health. Specialty-level assessment and treatment are important for precise differential diagnosis and treatment when central nervous system disease recurrence can mimic psychiatric symptoms.

  32. Correspondence

    1. Reply to sarcopenia is more than simply documenting low skeletal muscle mass

      Matthew K. Tollefson and Sarah P. Psutka

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29017

    2. Sarcopenia is more than simply documenting low skeletal muscle mass

      Umit Cintosun, Ilker Tasci, Vildan Binay Safer and Umut Safer

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29016

  33. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial

      Hoda Badr, Cardinale B. Smith, Nathan E. Goldstein, Jorge E. Gomez and William H. Redd

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.29009

      Advanced lung cancer patients and their caregivers who receive an intervention show significant improvements in depression, anxiety, and caregiver burden in comparison with those receiving usual medical care. Large effect sizes (d > 1.2) are also shown for patient and caregiver competence and relatedness and caregiver autonomous motivation for providing care.

    2. Disparities Research
      Attitudes toward molecular testing for personalized cancer therapy

      Rafeek A. Yusuf, Deevakar Rogith, Shelly R. A. Hovick, Susan K. Peterson, Allison M. Burton-Chase, Bryan M. Fellman, Yisheng Li, Carolyn McKinney, Elmer V. Bernstam and Funda Meric-Bernstam

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.28966

      The authors assess the attitudes of 100 breast cancer patients regarding molecular testing for personalized therapy and research with a questionnaire. Most patients are willing to undergo molecular testing and minimally invasive procedures to guide approved or experimental therapy, but there are significant differences in attitudes toward molecular testing between racial groups.

  34. Correspondence

    1. Reply to Charlson score and competing mortality

      Timothy J. Daskivich, Mark S. Litwin and Christopher Saigal

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.28955

    2. Charlson score and competing mortality

      Michael Froehner, Rainer Koch and Manfred P. Wirth

      Article first published online: 10 SEP 2014 | DOI: 10.1002/cncr.28958

  35. Erratum

    1. You have free access to this content
    2. You have free access to this content
  36. Original Articles

    1. Discipline

      Complementary Medicine
      Randomized, placebo-controlled trial of K1 acupoint acustimulation to prevent cisplatin-induced or oxaliplatin-induced nausea

      Yehua Shen, Luming Liu, Joseph S. Chiang, Zhiqiang Meng, M. Kay Garcia, Zhen Chen, Huiting Peng, Wenying Bei, Qi Zhao, Amy R. Spelman and Lorenzo Cohen

      Article first published online: 9 SEP 2014 | DOI: 10.1002/cncr.28973

      This randomized, placebo-controlled trial investigated whether electrostimulation of acupoint K1 could control chemotherapy-induced nausea and vomiting among patients with primary or metastatic liver cancer. Electrostimulation of acupoint K1 did not appear to result in the prevention of acute or delayed cisplatin-induced or oxaliplatin-induced nausea or vomiting when combined with antiemetics.

    2. Disease Site

      Neuro-Oncology
      Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma

      Yi-Bin Chen, Tracy Batchelor, Shuli Li, Ephraim Hochberg, Mark Brezina, Sooae Jones, Candice Del Rio, Morgan Curtis, Karen K. Ballen, Jeffrey Barnes, Andrew S. Chi, Jorg Dietrich, Jessica Driscoll, Elizabeth R. Gertsner, Fred Hochberg, Ann S. LaCasce, Steven L. McAfee, Thomas R. Spitzer, Lakshmi Nayak and Philippe Armand

      Article first published online: 9 SEP 2014 | DOI: 10.1002/cncr.29023

      Using high-dose systemic rituximab may allow higher concentrations to penetrate the central nervous system. This article presents a phase 2 trial combining high-dose rituximab with standard autologous stem cell transplantation and shows compelling results in patients with central nervous system involvement by non-Hodgkin lymphoma.

  37. Review Articles

    1. Multimodal imaging for improved diagnosis and treatment of cancers

      Clare M. C. Tempany, Jagadeesan Jayender, Tina Kapur, Raphael Bueno, Alexandra Golby, Nathalie Agar and Ferenc A. Jolesz

      Article first published online: 9 SEP 2014 | DOI: 10.1002/cncr.29012

      Multimodal molecular imaging enables the detection, characterization, diagnosis, and treatment of cancer. Used in real time during therapy, it allows more complete cancer therapy with minimal collateral damage to healthy surrounding tissue. Image-guided therapy using advanced multimodality imaging for brain, prostate, and lung cancers is reviewed.

  38. Original Articles

    1. Discipline

      Epidemiology
      Physician-reported barriers to referring cancer patients to specialists: Prevalence, factors, and association with career satisfaction

      Daniel H. Kwon, Diana M. Tisnado, Nancy L. Keating, Carrie N. Klabunde, John L. Adams, Afshin Rastegar, Mark C. Hornbrook and Katherine L. Kahn

      Article first published online: 5 SEP 2014 | DOI: 10.1002/cncr.29019

      Many physicians experience barriers to specialty referral for cancer patients. Physicians in large, highly managed care practices report fewer barriers, and high reporting of barriers is associated with low career satisfaction.

    2. Disease Site

      Skin
      Clinico-morphological features of BRAF inhibition–induced proliferative skin lesions in cancer patients

      Viswanath Reddy Belum, Alyx C. Rosen, Natalia Jaimes, George Dranitsaris, Melissa P. Pulitzer, Klaus J. Busam, Ashfaq A. Marghoob, Richard D. Carvajal, Paul B. Chapman and Mario E. Lacouture

      Article first published online: 3 SEP 2014 | DOI: 10.1002/cncr.28980

      Despite improved cancer outcomes with BRAF inhibitors, the characterization and management of the associated adverse events exemplify the challenges of survivorship care. Published studies involving BRAF inhibitors reflect an adverse event profile that is characterized by proliferative skin lesions (keratoacanthomas/cutaneous squamous cell carcinomas and verrucous lesions), maculopapular rashes, and hyperkeratosis. With regulatory approval and expanding use of vemurafenib and dabrafenib, oncologists will encounter proliferative skin lesions more often. Recognition of their key identifying features and appropriate management are crucial for ensuring consistent dosing of life-saving anticancer therapy, maintenance of health-related quality of life, and lower morbidity associated with adverse event management.

    3. Genitourinary Disease
      Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma

      Ahmed Q. Haddad, Payal Kapur, Nirmish Singla, Jay D. Raman, Matthew T. Then, Philipp Nuhn, Alexander Buchner, Patrick Bastian, Christian Seitz, Shahrokh F. Shariat, Karim Bensalah, Nathalie Rioux-Leclercq, Arthur Sagalowsky, Yair Lotan and Vitaly Margulis

      Article first published online: 3 SEP 2014 | DOI: 10.1002/cncr.28976

      Alteration of mammalian target of rapamycin biomarkers predicts survival outcomes in patients with clear cell renal carcinoma. This marker panel has prognostic value in addition to standard clinical and pathologic predictors of outcome.

    4. Breast Disease
      You have free access to this content
      Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel

      Nadine Tung, Chiara Battelli, Brian Allen, Rajesh Kaldate, Satish Bhatnagar, Karla Bowles, Kirsten Timms, Judy E. Garber, Christina Herold, Leif Ellisen, Jill Krejdovsky, Kim DeLeonardis, Kristin Sedgwick, Kathleen Soltis, Benjamin Roa, Richard J. Wenstrup and Anne-Renee Hartman

      Article first published online: 3 SEP 2014 | DOI: 10.1002/cncr.29010

      Using a next-generation sequencing 25-gene panel, the frequency of mutations for patients with breast cancer in genes other than BRCA1/2 is 4.3%, and most of the mutations (3.9%) are in genes associated with breast/ovarian cancer. Approximately half of patients with mutations in genes other than BRCA1/2 are identified in moderate-penetrance genes for which the efficacy of medical management is less well defined.

    5. Hepatobiliary Disease
      KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases

      Nancy E. Kemeny, Joanne F. Chou, Marinela Capanu, Alexandra N. Gewirtz, Andrea Cercek, T. Peter Kingham, William R. Jarnagin, Yuman C. Fong, Ronald P. DeMatteo, Peter J. Allen, Jinru Shia, Celina Ang, Efsevia Vakiani and Michael I. D'Angelica

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28954

      Among patients with resected colorectal liver metastases treated with adjuvant therapy, those with mutated KRAS appear to have significantly higher incidences of bone, brain, and lung metastases compared with patients with wild-type KRAS. In addition, KRAS-mutated patients had a worse recurrence-free survival (median, 26.4 months vs 14.5 months for patients with KRAS wild-type; In addition, KRAS-mutated patients had a worse recurrence-free survival (median, 14.5 months) versus median 26.4 months for patients with KRAS wild-type.

  39. Commentary

    1. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria

      Ryan D. Gentzler, Sarah E. Yentz, Melissa L. Johnson, Alfred W. Rademaker and Jyoti D. Patel

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28956

      ASCO abstracts for NSCLC trials over the last 11 years have shown an increasing rate of positive PFS and OS outcomes. Molecular biomarker and histology selection criteria in trials may account for this increase in positive outcomes.

  40. Original Articles

    1. Disease Site

      Melanoma
      Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients

      Nathaniel H. Fleming, Judy Zhong, Inês Pires da Silva, Eleazar Vega-Saenz de Miera, Bobbi Brady, Sung Won Han, Doug Hanniford, Jinhua Wang, Richard L. Shapiro, Eva Hernando and Iman Osman

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28981

      Serum-based miRNAs have prognostic clinical utility in melanoma patients for the prediction and monitoring of recurrence. Key serum miRNAs are predicted to play biological roles in melanoma disease by bioinformatics analysis.

  41. Editorial

    1. You have full text access to this OnlineOpen article
      KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection?

      Kjetil Søreide, Oddvar M. Sandvik and Jon A. Søreide

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28979

      Patients with colorectal cancer have experienced remarkable progress in a range of surgical and oncologic management strategies over the past few years, with a corresponding improvement in survival. The KRAS mutation may be a biomarker of cancer biology and prognosis, but also reflects patient selection.

  42. Original Articles

    1. Discipline

      Clinical Trials
      Cancer survivors' uptake and adherence in diet and exercise intervention trials: An integrative data analysis

      Rebecca N. Adams, Catherine E. Mosher, Cindy K. Blair, Denise C. Snyder, Richard Sloane and Wendy Demark-Wahnefried

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.28978

      Cancer survivors' demographic and medical characteristics predict their interest and participation in diet and exercise intervention trials. The findings reported here can help to guide trial procedures to enhance patient diversity and representation and assist with the interpretation of generalizability.

    2. Epidemiology
      You have full text access to this OnlineOpen article
      Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010

      Haley R. Gittleman, Quinn T. Ostrom, Chaturia D. Rouse, Jacqueline A. Dowling, Peter M. de Blank, Carol A. Kruchko, J. Bradley Elder, Steven S. Rosenfeld, Warren R. Selman, Andrew E. Sloan and Jill S. Barnholtz-Sloan

      Article first published online: 25 AUG 2014 | DOI: 10.1002/cncr.29015

      Time trends in cancer incidence rates are important to measure the changing burden of cancer on a population over time. In adults, there were significant decreases noted in the incidence of colon, breast, lung, prostate, and malignant central nervous system tumors (CNST), but a significant increase in nonmalignant CNST. There were significant increases observed in malignant CNST and nonmalignant CNST among adolescents and significant increases in acute lymphocytic leukemia, non-Hodgkin lymphoma, and malignant CNST noted in children.

  43. Erratum

    1. You have free access to this content
  44. Original Articles

    1. Discipline

      Clinical Trials
      Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer

      Mehmet Asim Bilen, Marcella M. Johnson, Paul Mathew, Lance C. Pagliaro, John C. Araujo, Ana Aparicio, Paul G. Corn, Nizar M. Tannir, Franklin C. Wong, Michael J. Fisch, Christopher J. Logothetis and Shi-Ming Tu

      Article first published online: 22 AUG 2014 | DOI: 10.1002/cncr.28971

      To the authors' knowledge, this is the first study that combines androgen-deprivation therapy with a radiopharmaceutical agent for the treatment of patients with advanced castrate-sensitive prostate cancer. Although an improvement in progression-free survival has not been detected, the results suggest a favorable outcome for those patients with a greater tumor burden in the bone.

  45. Editorials

    1. Are patient preferences for end-of-life care socially influenced? Examining racial disparities in advance care planning

      Fay J. Hlubocky

      Article first published online: 21 AUG 2014 | DOI: 10.1002/cncr.28969

      Future research should continue empirical investigations into the social influences and additional factors responsible for the modification of preferences among racially/ethnically diverse patients with terminal cancer, because these factors would be informative for the development of a culturally sensitive, patient-centered advance planning intervention for such patients. Advance care planning interventions have the potential to significantly challenge current clinical and research practice paradigms pertaining to the provision of end-of-life care to terminal cancer patients, with particular relevance to racial and ethnic minorities who are disproportionately more likely to receive aggressive life-sustaining care.

  46. Original Articles

    1. Discipline

      Disparities Research
      End-of-life treatment preferences: A key to reducing ethnic/racial disparities in advance care planning?

      Melissa M. Garrido, Shannon T. Harrington and Holly G. Prigerson

      Article first published online: 21 AUG 2014 | DOI: 10.1002/cncr.28970

      Patient interview data are used to demonstrate that, although patient preferences against life-prolonging care differ dramatically by race/ethnicity, they are uniformly significantly associated with do-not-resuscitate order completion rates across racial/ethnic groups of patients with advanced cancer.

    2. Quality of Life
      You have full text access to this OnlineOpen article
      Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life

      Christopher R. Spencer, Hiram A. Gay, Bruce H. Haughey, Brian Nussenbaum, Douglas R. Adkins, Tanya M. Wildes, Todd A. DeWees, James S. Lewis Jr. and Wade L. Thorstad

      Article first published online: 20 AUG 2014 | DOI: 10.1002/cncr.28938

      Eliminating radiation therapy to the contralateral retropharyngeal lymph nodes and contralateral high level II lymph nodes in the clinically uninvolved neck does not increase the risk of recurrence in these areas. Limiting radiation treatment volume, as such, translates into improved patient-reported quality of life.

    3. Disease Site

      Neuro-Oncology
      Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma

      Jaime Gállego Pérez-Larraya, Sophie Paris, Ahmed Idbaih, Caroline Dehais, Florence Laigle-Donadey, Soledad Navarro, Laurent Capelle, Karima Mokhtari, Yannick Marie, Marc Sanson, Khê Hoang-Xuan, Jean-Yves Delattre and Alain Mallet

      Article first published online: 19 AUG 2014 | DOI: 10.1002/cncr.28949

      A combined profile of preoperative insulin-like growth factor-binding protein 2 (IGFBP-2), glial fibrillary acidic protein (GFAP), and chitinase-3-like protein 1 (YKL-40) plasma levels could serve as a potential diagnostic tool for patients with glioblastoma multiforme (GBM). IGFBP-2 levels appear to constitute an independent prognostic factor in patients with GBM.

  47. Correspondence

  48. Original Articles

    1. Disease Site

      Hematologic Malignancies
      IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma

      Eileen M. Boyle, Guillemette Fouquet, Stéphanie Guidez, Sarah Bonnet, Helene Demarquette, Remy Dulery, Charles Herbaux, Marie Pierre Noel, Salomon Manier, Suzanna Schraen, Brigitte Onraed, Jean-Luc Faucompré, Bernadette Hennache, Marie Odile Petillon, Claire Mathiot, Herve Avet-Loiseau, Thierry Facon, Stephen J. Harding, Philippe Moreau and Xavier Leleu

      Article first published online: 12 AUG 2014 | DOI: 10.1002/cncr.28946

      The immunoglobulin (Ig) A Hevylite test is a new tool that may be used to adequately monitor patients with IgA multiple myeloma. By measuring isotype paired suppression, it offers additional prognostic information for the management of patients with IgA multiple myeloma.

    2. Discipline

      Pediatric Oncology
      Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma

      Jean S. Lee, Steven G. DuBois, W. John Boscardin, Rosanna L. Wustrack and Robert E. Goldsby

      Article first published online: 12 AUG 2014 | DOI: 10.1002/cncr.28936

      As patients with osteosarcoma become long-term survivors, increasing attention has turned to the burden of late effects. Survivors of osteosarcoma are at an increased risk of secondary malignant neoplasms compared with the baseline population, with an increased risk noted among patients treated in the more recent era.

    3. Disease Site

      Hematologic Malignancies
      Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

      Cristina Motlló, Josep-María Ribera, Mireia Morgades, Isabel Granada, Pau Montesinos, José González-Campos, Pascual Fernández-Abellán, Mar Tormo, Concepción Bethencourt, Salut Brunet, Jesús-María Hernández-Rivas, María-José Moreno, Josep Sarrà, Eloy del Potro, Pere Barba, Teresa Bernal, Carlos Grande, Javier Grau, José Cervera, Evarist Feliu and PETHEMA Group, Spanish Society of Hematology

      Article first published online: 12 AUG 2014 | DOI: 10.1002/cncr.28950

      After reviewing the karyotypes of 881 adult ALL patients treated according to the protocols of the PETHEMA Group between 1993 and 2012, the complex karyotype and the monosomal karyotype did no confer worse prognosis.

    4. Genitourinary Disease
      Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients

      Lisa Derosa, Luca Galli, Paola Orlandi, Anna Fioravanti, Teresa Di Desidero, Andrea Fontana, Andrea Antonuzzo, Elisa Biasco, Azzurra Farnesi, Riccardo Marconcini, Giulio Francia, Romano Danesi, Alfredo Falcone and Guido Bocci

      Article first published online: 8 AUG 2014 | DOI: 10.1002/cncr.28953

      The present multicenter, prospective, non-randomized phase II clinical study demonstrates that the combination of docetaxel and prednisone plus metronomic cyclophosphamide and celecoxib is effective as a first-line treatment in patients with mCRPC, and that it shows favorable toxicity. Moreover, the investigation of -1154A/G VEGF polymorphism, and of VEGF and bFGF plasma levels after the first cycle of chemotherapy suggests that these pharmacodynamic indices may be useful markers to predict a better outcome.

    5. Chest and Lung Disease
      Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib

      Boe S. Sorensen, Lin Wu, Wen Wei, Julie Tsai, Britta Weber, Ebba Nexo and Peter Meldgaard

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28964

      Using a new method that allows for the quantification of the level of tumor DNA with epidermal growth factor receptor (EGFR) mutations in a blood sample, the authors were able to monitor the effect of the EGFR-targeting agent erlotinib in patients with lung cancer. Most interestingly, the results of the current study demonstrate that a mutation (T790M) causing erlotinib resistance can be detected in the blood up to 1 year earlier than disease progression can be identified by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.

  49. Editorials

    1. Monitoring cancer through the blood

      Cloud P. Paweletz and Pasi A. Jänne

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28967

      Tumor biopsies remain the gold standard for the evaluation of genetic changes in tumors either at diagnosis or after treatment with targeted therapies. However, this is not always feasible and can seldom be performed more than once. Noninvasive techniques that measure the allelic burden in blood have the potential to realize genotype-directed cancer therapy. These technologies can potentially be used for noninvasive tumor genotyping and also provide an opportunity for disease monitoring. Several non-invasive genotyping technologies are currently under development and being evaluated in patients treated with targeted therapies.

  50. Correspondence

    1. In-bag morcellation for presumed myoma retrieval at laparoscopy

      Giorgio Bogani, Maurizio Serati, Stefano Uccella and Fabio Ghezzi

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28959

  51. Original Articles

    1. Discipline

      Outcomes Research
      Health-related quality of life as a prognostic factor in patients with advanced cancer

      Jennifer L. Steel, David A. Geller, Tiana L. Robinson, Alexandra Y. Savkova, Deborah S. Brower, J. Wallis Marsh and Allan Tsung

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28902

      Health-related quality of life was found to be prognostic of survival in patients with hepatocellular and cholangiocarcinoma while controlling for demographics, disease-specific factors, and treatment-related factors.

    2. Disease Site

      Head and Neck Disease
      Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck

      Nabil F. Saba, Selwyn J. Hurwitz, Kelly Magliocca, Sungjin Kim, Taofeek K. Owonikoko, Donald Harvey, Suresh S. Ramalingam, Zhengjia Chen, Jackie Rogerio, Jennifer Mendel, Scott A. Kono, Colleen Lewis, Amy Y. Chen, Kristin Higgins, Mark El-Deiry, Trad Wadsworth, Jonathan J. Beitler, Dong M. Shin, Shi-Yong Sun and Fadlo R. Khuri

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28965

      This article describes clinical, pharmacokinetic, and tissue biomarker correlative studies in a phase 1 trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck combining for the first time a platinum (carboplatin) with cetuximab and everolimus. The combination of 2 biomarkers, the p-p44/42 weighted index and the phosphorylated mammalian target of rapamycin weighted index, has a high predictive discrimination power for a clinical response (areas under the curve of 0.9583 and 0.9167, respectively). A 2-compartment mixed-effects pharmacokinetic model is consistent with previously described studies. The maximum tolerated dose of everolimus in this combination is 2.5 mg every other day. Despite the observed toxicities, this combination is associated with an encouraging response rate and progression-free survival and may deserve further investigation in a better selected population.

    3. Discipline

      Epidemiology
      Agent Orange exposure and cancer incidence in Korean Vietnam veterans: A prospective cohort study

      Sang-Wook Yi and Heechoul Ohrr

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28961

      Low levels of exposure to Agent Orange (2,3,7,8-tetrachlorodibenzo-p-dioxin) decades earlier may increase an individual's overall cancer risk. Exposure to Agent Orange may increase the risk of cancers of the mouth, salivary glands, stomach, and liver.

  52. Editorials

    1. Challenges in investigating the association between Agent Orange and cancer: Site-specific cancer risk and accuracy of exposure assessment

      Thomas H. Sinks

      Article first published online: 7 AUG 2014 | DOI: 10.1002/cncr.28962

      The findings of the study by Yi and Ohrr in the current issue of Cancer add to our overall understanding of the health risks from exposures to Agent Orange. Large numbers of individuals were potentially exposed to Agent Orange during the Vietnam War and this report reminds us of the critical importance of accurate exposure assessment and the desire for epidemiologic studies to provide scientific clarity, even in the most difficult of circumstances.

VIEW

  1. 1 - 100
  2. 101 - 146

SEARCH

SEARCH BY CITATION